Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)
✉ Email this page to a colleague
AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)
| Docket | ⤷ Subscribe | Date Filed | 2018-10-12 |
| Court | District Court, N.D. West Virginia | Date Terminated | 2023-03-08 |
| Cause | 35:271 Patent Infringement | Assigned To | John Preston Bailey |
| Jury Demand | None | Referred To | Robert W. Trumble |
| Patents | 10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-10-12 | 1 | Complaint (NOT for attorney use) | expiration of U.S. Patent Nos. 7,759,328 (“the ‘328 patent”), 8,143,239 (“the ‘239 patent”), 8,575,137 (… The Patents-in-Suit 16. United States Patent No. 7,759,328 (“the ‘328 patent”), entitled…Exhibit A - Patent Information, # 2 Exhibit B - Patent Information, # 3 Exhibit C - Patent Information…of the ‘328 patent. 18. United States Patent No. 8,143,239 (“the ‘239 patent”), entitled…of the ‘239 patent. 20. United States Patent No. 8,575,137 (“the ‘137 patent”), entitled | External link to document |
| 2020-08-12 | 317 | Memorandum & Opinion | “the ’239 patent”), 8,575,137 (“the ’137 patent”), and the 10,166,247 (“the ’247 patent) (collectively…’328 patent, col. 1:21-24; ’239 patent, col. 1:25-28; ’137 patent, col. 1:26-30; ’247 patent, col.…328 patent, col. 1:46; ’239 patent, col. 1:49; ’137 patent, col. 1:48; ’247 patent, …‘328 patent, col. 2:17-21; ’239 patent, col. 2:22-26; ’137 patent, col. 2:18-22; ’247 patent, col.…Specifically, the patents at issue are U.S. Patent Nos. 7,759,328 (“the ’328 patent”), 8,143,239 | External link to document |
| 2021-03-02 | 431 | Memorandum & Opinion | infringement claims for U.S. Patent No. 10,166,247 (the “’247 patent”) (Dkt. No. 89), and deleted…States Patent No. 8,143,239 (“the ’239 Patent”); and claims 10 and 19 of United States Patent No. 8,575,137…History of Patents-In-Suit The Patent and Trademark Office (“PTO”) issued the patents-in- suit…, 13, and 14 of United States Patent No. 7,759,328 (“the ’328 Patent”); claims 12, 13, 18, and 19 …8,575,137 (“the ’137 Patent”) (collectively, “the asserted claims” or the “patents-in-suit”) are | External link to document |
| 2022-03-30 | 533 | Status Report | of trial to invalidity of U.S. Patent 10,166,247 (“the ’247 patent”) and are negotiating a stipulation…247 patent. Mylan has always and continues to maintain its defense that the ’247 patent is … is permitted to assert obviousness of the ’247 patent. AstraZeneca’s position is that law of the …nonobviousness as to the claims of the ’247 patent, all of which are directed to compositions comprising…relitigating obviousness of similar claims in related patent); Smith Int’l v. Hughes Tool, 759 F.2d 1572 | External link to document |
| 2022-04-07 | 539 | Stipulation and Order | Circuit Patents”); and 10,166,247 (“’247 patent) (together with the Federal Circuit Patents, the ….S. Patent Nos. 7,759,328 (“’328 patent”); 8,143,239 (“’239 patent”); 8,575,137 (“’137 patent”) (collectively…of the patents-in-suit, specifically, claims 1, 4, 5, 7, 9, 10, 13 and 14 of the ’328 patent (“the …the ’239 patent (“the ’239 Asserted Claims”); claims 1-6, 9, 10 and 13-53 of the ’137 patent (“the ’…, 13, and 14 of the ʼ328 patent; claims 12, 13, 18, and 19 of the ’239 patent; and claims 10 and 19 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
